THC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenet Healthcare Corp (THC) does not present a compelling buy opportunity for a beginner, long-term investor at this moment. The stock's technical indicators are neutral, options data shows mixed sentiment, and recent Congress trading data reflects caution with more selling activity. While analysts maintain an overall positive long-term outlook, recent price target reductions and lack of immediate positive catalysts suggest waiting for more clarity or a better entry point.
The MACD is positively contracting but remains above 0, indicating a neutral to slightly bullish trend. RSI is at 46.479, in the neutral zone, showing no clear overbought or oversold conditions. Moving averages are converging, and the stock is trading near its pivot level of 171.404, with resistance at 181.823 and support at 160.985. Overall, the technical indicators suggest a lack of strong momentum in either direction.
Hedge funds have significantly increased their buying activity by 337.36% over the last quarter. Analysts maintain an overweight rating, citing Tenet's ability to manage costs and navigate headwinds effectively. Q1 results showed a 3% EBITDA beat, and management hinted at potential upside in Q2.
Congress trading data shows two recent sale transactions totaling $1.6M to $6.5M, indicating caution from influential figures. Analysts have lowered price targets across the board, reflecting moderated expectations. The stock has declined 3.32% in the regular market session, and technical indicators show no strong upward momentum.
Financial data for the latest quarter is unavailable, but analysts highlighted a 3% EBITDA beat in Q1 driven by acuity gains and expense management. Management maintained guidance but noted utilization moderation.
Analysts have lowered price targets but remain generally positive on the stock's long-term value. Multiple firms, including Barclays, Morgan Stanley, and KeyBanc, maintain overweight ratings, citing Tenet's ability to manage costs and deliver consistent execution despite industry headwinds.
